... trial of Puma's drug neratinib at the 2019 San Antonio Breast Cancer Symposium (SABCS) that is currently taking place in San Antonio, Texas.
News
- Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended ...
- Life Science Big News Roundup: Algernon Selects NP-120 for its Lead Phase 2 Trial; BriaCell ...
Life Science Big News Roundup: Algernon Selects NP-120 for its Lead ... Data as Presented at the 2019 San Antonio Breast Cancer Symposium®.
- Recon: Sarepta Wins Early Approval for DMD Drug After Earlier Rejection; PhRMA Sues Over ...
A third DMD approval, analysts predict (Endpoints); Biotech veteran Chris ... Pharmaceutical & Biotechnology: Study Results, Filings & Designations ... Metastatic Triple Negative Breast Cancer (mTNBC) at the 2019 San Antonio ...
- Anixa Biosciences, Inc. (ANIX) Stock Price Hits 52 Week Low Today
Anixa Biosciences, Inc. (ANIX) Stock Price Hits 52 Week Low Today ... The stock of Anixa Biosciences, Inc. (NASDAQ:ANIX) hit a new 52-week low ... up Urology San Antonio for Cchek prostate cancer study – Seeking Alpha” with ...
- The Daily Biotech Pulse: Second Time's The Charm For Sarepta, Pfizer's Xeljanz Snags Third ...
The following is a roundup of top developments in the biotech space over the last 24 hours. ... (Biotech stocks that hit 52-week highs on Dec. ... presented interim data at the San Antonio Breast Cancer Symposium from the ongoing ...